Results 61 to 70 of about 45,526 (248)

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. [PDF]

, 2016
CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue.
Calabretta, Bruno, Canonico, Pier Luigi, Condorelli, Fabrizio, De Dominici, Marco, Genazzani, Armando A, Gnemmi, Ilaria, Mariani, Samanta A., Minassi, Alberto, Minieri, Valentina, Riva, Beatrice, Salomoni, Paolo   +10 more
core   +2 more sources

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Optimized Treatment Schedules for Chronic Myeloid Leukemia [PDF]

, 2016
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients.
Dingli, David, Foo, Jasmine, He, Qie, Leder, Kevin, Zhu, Junfeng   +4 more
core   +7 more sources

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source

The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias [PDF]

Cell Death & Differentiation, 2008
Bcr-Abl tyrosine kinase (TK) inhibitors are promising therapeutic agents for Bcr-Abl-positive (Bcr-Abl(+)) leukemias. Although they are known to promote caspase-mediated apoptosis, it remains unclear whether caspase-independent cell death-inducing mechanisms are also triggered.
Y, Kamitsuji, J, Kuroda, S, Kimura, S, Toyokuni, K, Watanabe, E, Ashihara, H, Tanaka, Y, Yui, M, Watanabe, H, Matsubara, Y, Mizushima, Y, Hiraumi, E, Kawata, T, Yoshikawa, T, Maekawa, T, Nakahata, S, Adachi   +16 more
openaire   +2 more sources

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia [PDF]

, 2014
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and ...
Bilban, Martin, Blatt, Katharina, Cerny-Reiterer, Sabine, Herndlhofer, Susanne, Herrmann, Harald, Hoermann, Grego, Holyoake, Tessa L., Mannhalter, Christine, Mayerhofer, Matthias, Rulicke, Thomas, Sadovnik, Irina, Sperr, Wolfgang R., Stefanzl, Gabriele, Streubel, Berthold, Valent, Peter, Willmann, Michael   +15 more
core   +1 more source

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, EarlyView.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source

Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2014
Objective: This study investigated the occurrence of the p190 and p210 break point clusterregion-Abelson (BCR-ABL) rearrangements in adults with acute lymphoblastic leukemia and possible associations with clinical and laboratory characteristics and ...
Ilana de França Azevedo, Rui Milton Patrício da Silva Júnior, Audrey Violeta Martins de Vasconcelos, Washington Batista das Neves, Fárida Coeli de Barros Correia Melo, Raul Antônio Morais Melo   +5 more
doaj   +1 more source

Allosterische Kinaseinhibitoren [PDF]

, 2017
Background. Inhibition of the kinase activity of the BCR-ABL1 oncoprotein by an allosteric mechanism of action facilitates alternative treatment options for chronic myeloid leukemia (CML) patients who cannot be adequately treated with conventional ...
Hantschel, Oliver, Ottmann, Oliver G.
core   +2 more sources

Atypical Wounds in Chronic Graft‐Versus‐Host Disease and Peripheral Arterial Disease Caused by Tyrosine Kinase Inhibitors

JEADV Clinical Practice, EarlyView.
ABSTRACT The term “atypical wounds” primarily refers to lesions with immunological or cancerous etiologies. However, these wounds can also be drug‐induced. We report about a 32‐year‐old man with a 6‐year history of chronic myelogenous leukemia (CML) and chronic graft‐versus‐host disease (cGvHD) following an HLA‐compatible allogeneic stem cell ...
E. K. Stuermer, K. Malik, C. Willers, M. Augustin   +3 more
wiley   +1 more source